COMPLETED

Financial Toxicity and Quality of Life in Patients With TGCT

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

Official Title

Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors

Quick Facts

Study Start:2023-03-01
Study Completion:2025-02-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04531709

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \> 18 years of age
  2. * Patients with histologically or clinically confirmed germ cell tumor.
  3. * Completed treatment for germ cell tumor with multicycle (\> 2 cycles) / multiagent chemotherapy.
  4. * Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
  5. * Signed informed consent
  1. * Long-term survivors
  2. * Patients undergoing active chemotherapy
  3. * Patients who did not complete 1st line chemotherapy.

Contacts and Locations

Principal Investigator

Deepak Pruthi, MD
PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center at San Antonio

Study Locations (Sites)

Mays Cancer Center
San Antonio, Texas, 78229
United States

Collaborators and Investigators

Sponsor: The University of Texas Health Science Center at San Antonio

  • Deepak Pruthi, MD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center at San Antonio

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-01
Study Completion Date2025-02-04

Study Record Updates

Study Start Date2023-03-01
Study Completion Date2025-02-04

Terms related to this study

Additional Relevant MeSH Terms

  • Testicular Neoplasm